People In The News: Tracking The Latest Industry Personnel Changes
Executive Summary
New top leadership at Caisson Biotech, Kala Pharmaceuticals and BASi; Cubist Pharmaceuticals announces a pair of promotions; FDA hires a director for the Office of Generic Drugs; more personnel announcements in this month’s column.
You may also be interested in...
FDA Office Of Generic Drugs Director Has Brand Industry Background
Gregory Geba mostly has brand experience, but will be expected to lead OGD’s reorganization as it implements a new user fee program.
A New Chapter, A New CEO For Dendreon
Former Savient and ImClone CEO Johnson will be responsible for driving commercial expansion of Provenge in the U.S. and Europe. Mitchell Gold steps down as CEO after successfully getting the prostate cancer drug to market following an arduous FDA review but struggling with commercial complexities.
Celgene Bolsters Pipeline With Avila Acquisition
Celgene will acquire the Massachusetts biotech for $350 million upfront plus $575 million in potential milestones related to Avila’s lead compound as well as other compounds to emerge from its technology platform.